Syndecan-4 is required for VE-Cadherin trafficking during pathological angiogenesis
Authors:
- Giulia De RossiGRGiulia De Rossi
- Maria VähätupaMVMaria Vähätupa
- Enrico CristanteECEnrico Cristante
- Sidath E. LiyanageSLSidath E. Liyanage
- Ulrike MayUMUlrike May
- Laura PellinenLPLaura Pellinen
- Saara AittomäkiSASaara Aittomäki
- Zuzet Martinez CordovaZCZuzet Martinez Cordova
- Marko PesuMPMarko Pesu
- Hannele Uusitalo-JärvinenHUHannele Uusitalo-Järvinen
- James W. BainbridgeJBJames W. Bainbridge
- Tero A.H. JärvinenTJTero A.H. Järvinen
Preprint
Abstract
New blood vessel formation, or angiogenesis, is characteristic of chronic diseases such as cancer, rheumatoid arthritis and vision-threatening conditions. Vascular Endothelial growth factor (VEGFA) and its receptor VEGFR2 drive neovascularization and hyperpermeability in these pathologies. One consequence of VEGFR2 activation is decreased stability of endothelial cell (EC) junctions through internalization of VE-Cadherin, allowing re-arrangement of sprouting ECs. Evidence suggests roles for heparan sulfate proteoglycans in angiogenesis and we show that Syndecan-4 (SDC4) expression is upregulated during pathological angiogenesis and is required for efficient VE-Cadherin internalization. Angiogenic responses in both tumor and neovascular eye disease models are impaired in Syndecan-4 null mice (Sdc4-/-), as is dermal hyper-permeability response to VEGFA. We show SDC4 resides at EC junctions and interacts with VE-Cadherin, an association lost upon VEGFA-stimulation, and this is SDC4 phosphorylation-dependent. Finally, we show that pathological angiogenic responses can be inhibited in a model of age-related macular degeneration by targeting SDC4. This study identifies SDC4 as a key component of VE-Cadherin trafficking and, as such, a critical regulator of pathological angiogenesis and vascular permeability.Keywords
This publication has 47 references indexed in Scilit:
- Syndecan‐4 involves in the pathogenesis of rheumatoid arthritis by regulating the inflammatory response and apoptosis of fibroblast‐like synoviocytesJournal of Cellular Physiology, 2019
- N-terminal syndecan-2 domain selectively enhances 6-O heparan sulfate chains sulfation and promotes VEGFA165-dependent neovascularizationNature Communications, 2019
- Targeting VEGF in eye neovascularization: What's new?Pharmacological Research, 2016
- Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapyScience Translational Medicine, 2015
- Shed syndecan-2 inhibits angiogenesisDevelopment, 2014
- The role of differential VE-cadherin dynamics in cell rearrangement during angiogenesisNature Cell Biology, 2014
- Molecular mechanisms and clinical applications of angiogenesisNature, 2011
- Transmembrane Signaling ProteoglycansAnnual Review of Cell and Developmental Biology, 2010
- Molecular regulation of angiogenesis and lymphangiogenesisNature Reviews Molecular Cell Biology, 2007
- Endothelial cell–cell junctions: happy togetherNature Reviews Molecular Cell Biology, 2004